Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Molecular Pathway-based Umbrella Trial for First-line Precision Therapy With TROP2 in Patients With Locally Advanced or Metastatic TNBC (Future-Trop2 Study)

NCT05928780 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05928780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05928780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Molecular Pathway-based Umbrella Trial for First-line Precision Therapy With TROP2 in Patients With Locally Advanced or Metastatic TNBC (Future-Trop2 Study)
Lead sponsor
Fudan University
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 1, 2023
Completion date
September 1, 2025
Enrollment
125 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc - triple-negative breast cancer